Cytodyn

CytoDyn Inc. is a clinical-stage biotechnology company based in Vancouver, Washington, that specializes in the development of humanized monoclonal antibodies for treating human immunodeficiency virus (HIV) infection. Its primary product candidate, PRO 140, functions as an entry inhibitor, preventing HIV from infecting cells. CytoDyn is conducting multiple clinical trials for PRO 140, including a Phase IIb extension study as monotherapy for HIV, a Phase IIb/III study investigating its effectiveness in combination therapy, and a Phase Ib/II trial for metastatic triple-negative breast cancer. Additionally, the company explores potential applications of PRO 140 for other conditions, such as inflammatory disorders and autoimmune diseases. CytoDyn has also established a strategic partnership with Samsung BioLogics for the clinical and commercial manufacturing of its therapies.